Audio Posts and Shared Links

U.S. FDA grants priority review to Roche“s bispecific antibody Glofitamab

Listen to this article

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo

Roche (ROG.S) announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company’s bispecific antibody Glofitamab.

Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma.

The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023.

WP Radio
WP Radio